ESPE Abstracts

Quality of care of children living with diabetes varies widely around the world. Since discovering of insulin a hundred years ago, it’s still unavailable for a large part of children living with diabetes in developing world. According to World Health Organisation (2019), less than 13% of people living with diabetes in these countries have access to long acting insulin analogues. Thus, primary challenges of management of type I diabetes is reduction of mortality especially at diagnosis, but rapidly, the question of metabolic control and reduction of acute and chronic complications appears as secondary challenges of management for many teams around the world. Research of appropriate solutions for better care leads to discovery of new insulin, new technologies etc. The WHO selects essential medicines on the basis of their role in solving a public health issue, their innocuity, their efficacy and the cost/efficacy. Is long acting insulin responding to this criteria? We will therefore showed that diabetes care obey today to a “double standard”. We also state that, long acting insulin are benefit for children, adolescent and young adults living with type I diabetes in developing countries regarding to their nutrition challenges, prevention of acute and chronic conditions. Finally, we will review literature showing advantages of long acting insulin in type I diabetes compared to intermediate insulin, and its cost effectiveness.

Conclusion: Long acting insulin are important in better management of children with type I diabetes in low and middle income countries

Keys words: long acting insulin, developing countries, type I diabetes